Template:Bicalutamide levels during therapy with bicalutamide

From blackwiki
Jump to navigation Jump to search
Template documentation

See also

References

  1. 1.0 1.1 Cantarini M, Fuhr R, Morris T (2006). "Pharmacokinetics of two novel bicalutamide formulations in healthy male volunteers". Pharmacology. 77 (4): 171–8. doi:10.1159/000094599. PMID 16847400.
  2. 2.0 2.1 McKillop, D.; Boyle, G. W.; Cockshott, I. D.; Jones, D. C.; Phillips, P. J.; Yates, R. A. (1993). "Metabolism and enantioselective pharmacokinetics of Casodex in man". Xenobiotica. 23 (11): 1241–1253. doi:10.3109/00498259309059435. ISSN 0049-8254.
  3. 3.0 3.1 Cockshott, I.D.; Cooper, K.J.; Sweetmore, D.S.; Blacklock, N.J.; Denis, L. (1990). "The Pharmacokinetics of Casodex in Prostate Cancer Patients after Single and during Multiple Dosing". European Urology. 18 (3): 10–17. doi:10.1159/000463972. ISSN 0302-2838.
  4. 4.0 4.1 Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K, Cockshott ID (1998). "Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group". Eur. Urol. 33 (1): 39–53. doi:10.1159/000019526. PMID 9471040.
  5. 5.0 5.1 Tyrrell CJ, Iversen P, Tammela T, Anderson J, Björk T, Kaisary AV, Morris T (September 2006). "Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration". BJU International. 98 (3): 563–72. doi:10.1111/j.1464-410X.2006.06275.x. PMID 16771791.
  6. 6.0 6.1 6.2 Cockshott ID (2004). "Bicalutamide: clinical pharmacokinetics and metabolism". Clinical Pharmacokinetics. 43 (13): 855–878. doi:10.2165/00003088-200443130-00003. PMID 15509184.